Access
To read this story in full you will need to login or make a payment (see right).
Commentary
Nature 378, 534-536 (7 December 1995) | doi:10.1038/378534a0
The case for genomic patenting
George Posts
- SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia, Pennsylvania 19406-5939, USA.
Top of page
Abstract
Opposition to the patenting of genomic inventions threatens to erode the foundation of intellectual property rights needed to convert innovative research into new drugs, vaccines and diagnostic tests.
To read this story in full you will need to login or make a payment (see right).
